Cargando…
Retrospective analysis of premedication, glucocorticosteroids, and H(1)-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer
OBJECTIVES: We evaluated infusion-related reactions associated with cetuximab combination chemotherapy comprising an H1-receptor antagonist plus dexamethasone as anti-allergy premedications for patients with head and neck cancer. METHODS: We retrospectively evaluated 248 patients who received a cetu...
Autores principales: | Ikegawa, Kiwako, Suzuki, Shinya, Nomura, Hisanaga, Enokida, Tomohiro, Yamazaki, Tomoko, Okano, Susumu, Endo, Kazushi, Saito, Shinichiro, Yamaguchi, Masakazu, Tahara, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625540/ https://www.ncbi.nlm.nih.gov/pubmed/28606015 http://dx.doi.org/10.1177/0300060517713531 |
Ejemplares similares
-
Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016) -
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018) -
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018) -
The efficacy of single premedication with antihistamines for radiocontrast media hypersensitivity
por: Lee, So-Hee, et al.
Publicado: (2016) -
Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)